The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting.
Saved in:
| Title: | The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting. |
|---|---|
| Authors: | McNally, Paul1,2 (AUTHOR), Linnane, Barry3 (AUTHOR), Williamson, Michael1 (AUTHOR), Elnazir, Basil1,4 (AUTHOR), Short, Christopher5,6 (AUTHOR), Saunders, Clare5,6 (AUTHOR), Kirwan, Laura7 (AUTHOR), David, Rea1 (AUTHOR), Kemner-Van de Corput, Mariette P. C.8 (AUTHOR), Tiddens, Harm A.W.M.1 (AUTHOR), Davies, Jane C5,6 (AUTHOR), Cox, Des W1,9 (AUTHOR) desmond.cox@ucd.ie |
| Source: | Respiratory Research. 8/11/2023, Vol. 24 Issue 1, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
